ArticleFrontiers in psychology2026
Case Report: Amplified psychoanalysis? Psychoanalysis, OCD and MDMA in a clinical case study.
Article in Frontiers in psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article investigates the novel therapeutic approach of "amplified psychoanalysis" through a detailed examination of the Ygg case, which offers a descriptive single-case illustration of the integration of MDMA-assisted therapy with traditional psychoanalytic treatment for obsessive-compulsive disorder (OCD). The study explores how subjective experience induced by MDMA can interact with an ongoing analysis, potentially enhancing psychoanalytic processes by facilitating access to unconscious material and helping to move beyond therapeutic impasses. The work is presented as a psychoanalytic single-case clinical narrative, acknowledging the value of such cases for generating nuanced insights into psychological phenomena rather than for demonstrating efficacy. In this case, the integration of MDMA experiences within an established psychoanalytic framework appeared to create specific therapeutic opportunities: the altered states of consciousness were experienced by the patient as allowing more direct access to, and processing of, previously avoided memories and affects. This combination may be particularly promising for OCD, where traditional approaches often face limitations; however, its efficacy requires systematic investigation beyond this psychoanalytic single-case clinical narrative. The clinical process analysis highlights several putative processes of change, including enhanced emotional processing, a strengthened therapeutic alliance, and improved access to traumatic memories. The study aims to contribute to both psychedelic therapy and psychoanalytic practice by offering a novel therapeutic perspective on the treatment of OCD. It suggests that "amplified psychoanalysis" may represent a promising direction for future research with larger samples and formal outcome measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.